Treace Medical Concepts, Inc. has a significant shareholder position reported by Armistice Capital, LLC and Steven Boyd, who together are listed as reporting persons for the company’s common stock. They report beneficial ownership of 6,364,000 shares of Treace Medical Concepts common stock, representing 9.79% of the outstanding class as of the reporting date.
The shares are held directly by Armistice Capital Master Fund Ltd., for which Armistice Capital acts as investment manager under an Investment Management Agreement. Armistice Capital and Steven Boyd are reported as having shared voting and dispositive power over 6,364,000 shares and no sole voting or dispositive power. The Master Fund is stated to have the right to receive dividends and sale proceeds from these securities, while Armistice Capital and Mr. Boyd may be deemed to beneficially own the position through their management roles.
Positive
None.
Negative
None.
Key Figures
Shares beneficially owned:6,364,000 sharesPercent of class owned:9.79%Shared voting power:6,364,000 shares+4 more
7 metrics
Shares beneficially owned6,364,000 sharesCommon stock of Treace Medical Concepts reported by Armistice Capital and Steven Boyd
Percent of class owned9.79%Percentage of Treace Medical Concepts common stock beneficially owned
Shared voting power6,364,000 sharesShares with shared power to vote or direct the vote
Sole voting power0 sharesShares with sole power to vote or direct the vote
Shared dispositive power6,364,000 sharesShares with shared power to dispose or direct disposition
Sole dispositive power0 sharesShares with sole power to dispose or direct disposition
CUSIP89455T109CUSIP number for Treace Medical Concepts common stock
"may be deemed to beneficially own the securities of the Issuer"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
Investment Management Agreementfinancial
"pursuant to an Investment Management Agreement, Armistice Capital exercises voting"
An investment management agreement is a written contract that hires a professional to make buying, selling and strategy decisions for an investment account or fund, and sets out their duties, fees, risk limits, performance measures and reporting requirements. It matters to investors because the agreement determines who controls the money, how much the service costs, what risks are allowed, and how success or failure is measured—think of it as the service contract that defines expectations and remedies for a hired portfolio manager.
shared dispositive powerfinancial
"Shared Dispositive Power 6,364,000.00"
exempted companyfinancial
"The Master Fund, a Cayman Islands exempted company that is an investment"
Investment Company Act of 1940regulatory
"investment company registered under the Investment Company Act of 1940"
A U.S. federal law that sets the rulebook for pooled investment vehicles such as mutual funds, exchange-traded funds and similar money managers, requiring them to register with regulators, disclose holdings and fees, limit conflicts of interest, and follow governance standards. It matters to investors because these protections and transparency rules act like a referee and scoreboard, helping people compare funds, trust that managers follow fair practices, and spot hidden costs or risks.
FAQ
What percentage of Treace Medical Concepts (TMCI) shares does Armistice Capital report owning?
Armistice Capital and Steven Boyd report beneficial ownership of 9.79% of Treace Medical Concepts’ common stock, representing 6,364,000 shares over which they share voting and dispositive power through an investment management structure.
How many Treace Medical Concepts (TMCI) shares are beneficially owned by Armistice Capital?
The reporting persons disclose beneficial ownership of 6,364,000 shares of Treace Medical Concepts common stock. This position represents 9.79% of the class and is held directly by Armistice Capital Master Fund Ltd., an advisory client of Armistice Capital.
Who are the reporting persons in this TMCI Schedule 13G/A amendment?
The reporting persons are Armistice Capital, LLC and Steven Boyd. Armistice Capital serves as investment manager to Armistice Capital Master Fund Ltd., while Boyd is its managing member and may be deemed to beneficially own the same securities.
What voting and dispositive powers over TMCI shares does Armistice Capital report?
Armistice Capital and Steven Boyd report 0 shares with sole voting or dispositive power and 6,364,000 shares with shared voting and shared dispositive power, reflecting control exercised under an Investment Management Agreement with the Master Fund.
Which entity receives economic benefits from the TMCI shares held under this filing?
The filing states that Armistice Capital Master Fund Ltd., a Cayman Islands exempted company and advisory client of Armistice Capital, has the right to receive dividends and sale proceeds from the reported Treace Medical Concepts securities.
What is the relationship between Armistice Capital and the Master Fund in this TMCI filing?
Armistice Capital is described as the investment manager of Armistice Capital Master Fund Ltd. Under an Investment Management Agreement, it exercises voting and investment power over TMCI securities held by the Master Fund and may be deemed to beneficially own them.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 7)
Treace Medical Concepts, Inc.
(Name of Issuer)
Common stock, $0.001 par value
(Title of Class of Securities)
89455T109
(CUSIP Number)
06/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
89455T109
1
Names of Reporting Persons
Armistice Capital, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
6,364,000.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
6,364,000.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
6,364,000.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.79 %
12
Type of Reporting Person (See Instructions)
IA, OO
SCHEDULE 13G
CUSIP Number(s):
89455T109
1
Names of Reporting Persons
Steven Boyd
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
6,364,000.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
6,364,000.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
6,364,000.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.79 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Treace Medical Concepts, Inc.
(b)
Address of issuer's principal executive offices:
100 PALMETTO PARK PLACE, PONTE VEDRA, FL, 32081
Item 2.
(a)
Name of person filing:
Armistice Capital, LLC
Steven Boyd
Collectively, the "Reporting Persons"
(b)
Address or principal business office or, if none, residence:
Armistice Capital, LLC
510 Madison Avenue, 7th Floor
New York, New York 10022
United States of America
Steven Boyd
c/o Armistice Capital, LLC
510 Madison Avenue, 7th Floor
New York, New York 10022
United States of America
(c)
Citizenship:
Armistice Capital, LLC - Delaware; Steven Boyd - United States of America
(d)
Title of class of securities:
Common stock, $0.001 par value
(e)
CUSIP No.:
89455T109
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
6,364,000
(b)
Percent of class:
9.79%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
0
(ii) Shared power to vote or to direct the vote:
6,364,000
(iii) Sole power to dispose or to direct the disposition of:
0
(iv) Shared power to dispose or to direct the disposition of:
6,364,000
Armistice Capital, LLC ("Armistice Capital") is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Armistice Capital, LLC
Signature:
/s/ Steven Boyd
Name/Title:
Steven Boyd - Managing Member
Date:
08/14/2026
Steven Boyd
Signature:
/s/ Steven Boyd
Name/Title:
Steven Boyd
Date:
08/14/2026
Exhibit Information
JOINT FILING STATEMENT
PURSUANT TO RULE 13d-1(k)
The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.
Dated: August 14, 2026
Armistice Capital, LLC
By: /s/ Steven Boyd
Steven Boyd - Managing Member
Steven Boyd
By: /s/ Steven Boyd
